Hyperlipidemia and glucose intolerance in the post-renal transplant patient.
This review examines the relationship between renal transplantation and two important metabolic consequences: hyperlipidemia and glucose intolerance. Before cyclosporine, hypertriglyceridemia and hypercholesterolemia were common abnormalities that worsened in the cyclosporine era. In addition to obesity, steroid use, and reduced renal function, cyclosporine plays an independent role in elevating cholesterol levels, with particular reference to the modulation of the low-density lipoprotein receptor. Management includes maintaining low levels of steroid, manipulation of cyclosporine appropriately, diets low in fat and cholesterol, and an exercise program. Pharmacologic management in general revolves around the HMG-COA reductase drugs, which can be used safely if liver function tests and muscle enzymes are monitored. The unmasking of clinically important glucose intolerance occurs in 5 to 10% of patients in the cyclosporine era, not different from the earlier experience. Steroids and cyclosporine independently can worsen glucose tolerance to unmask a genetic predisposition to Type II diabetes in some and to even create glucose intolerance in otherwise normal individuals. Management is based on dietary and immunosuppressive drug dosing manipulations and the judicious use of oral hypoglycemic agents. Half of these recipients may ultimately need insulin. In summary, hyperlipidemia and glucose intolerance remain important metabolic consequences of renal transplantation that affect long-term patient survival unless recognized and treated.
Markell
M S
MS
Division of Nephrology, SUNY Health Science Center at Brooklyn 11203.
Armenti
V
V
Danovitch
G
G
Sumrani
N
N
D016572:Cyclosporine / Q000009:adverse effects; D018149:Glucose Intolerance / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007328:Insulin / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D012307:Risk Factors
D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; D007328:Insulin; D016572:Cyclosporine